Protagonist Therapeutics (PTGX) Tops Q1 EPS by 54c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q1 EPS of $0.05, $0.54 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $56.37 million versus the consensus estimate of $12.2 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• JPMorgan Starts Kanzhun Ltd (2076:HK) at Overweight
• Raymond James Upgrades Aecon Group (ARE:CN) (AEGXF) to Outperform